Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Keymed Biosciences's EBITDA for the
six
months ended in Dec. 2025 was HK$-426.9 Mil. Keymed Biosciences's Revenue for the
six
months ended in Dec. 2025 was HK$240.3 Mil. Therefore, Keymed Biosciences's EBITDA margin for the quarter that ended in Dec. 2025 was -177.64%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Keymed Biosciences EBITDA Margin % Related Terms
Keymed Biosciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Keymed Biosciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02162 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Keymed Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Keymed Biosciences EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Keymed Biosciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Keymed Biosciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keymed Biosciences (HKSE:02162) has a EBITDA Margin % of -177.64% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Keymed Biosciences and its competitors. According to the industry distribution chart, Keymed Biosciences ranks #459 out of 943 companies in the Biotechnology industry, placing it in the top 48.7%.
Is Keymed Biosciences' EBITDA Margin % too high?
Keymed Biosciences' current EBITDA Margin % is -177.64%. Based on the distribution chart, Keymed Biosciences ranks #459 out of 943 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Keymed Biosciences has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Keymed Biosciences' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Keymed Biosciences ranks #459 out of 943 companies for EBITDA Margin %. This puts Keymed Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Keymed Biosciences and its competitors. Keymed Biosciences's current EBITDA Margin % is -177.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keymed Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Keymed Biosciences (HKSE:02162) is currently considered Possible Value Trap. The stock's GF Value™ is HK$173.29, compared to a current price of HK$78.05 — trading 55% below its estimated fair value. The current EBITDA Margin % is -177.64%. Keymed Biosciences' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Keymed Biosciences (HKSE:02162), the current EBITDA Margin % is -177.64% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Keymed Biosciences (HKSE:02162) Overvalued in 2026?
Based on GuruFocus' analysis, Keymed Biosciences stock appears to be undervalued.
The current stock price of HK$78.05 is trading 55% below its estimated GF Value™ of HK$173.29.
GuruFocus considers Keymed Biosciences to be Possible Value Trap.
Key valuation signals for HKSE:02162:
EBITDA Margin %: -177.64%
GF Value™: HK$173.29 vs. price of HK$78.05 (55% below fair value)
No single metric tells the full story. See the HKSE:02162 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
46GF Score
Get the complete analysis for HKSE:02162
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02162 has been successfully added to your 
